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Abstract. Molecular markers have been proposed as a method of monitoring malaria drug resistance and could
potentially be used to prolong the life span of antimalarial drugs. Single nucleotide polymorphisms (SNPs) in the
Plasmodium falciparum gene pfmdr1 and increased gene copy number have been associated with in vitro drug resistance
but have not been well studied in vivo. In a prospective cohort study of malaria patients receiving mefloquine treatment
on the Thai-Myanmar border, there was no significant association between either pfmdr1 SNPs or in vitro drug sensi-
tivity and mefloquine resistance in vivo. Increased pfmdr1 gene copy number was significantly associated with recru-
descence (relative risk 2.30, 95% CI 1.27–4.15). pfmdr1 gene copy number may be a useful surveillance tool for
mefloquine-resistant falciparum malaria in Thailand.
INTRODUCTION
Each year, there are as many as 300 million cases of ma-
laria, causing severe anemia among children, perinatal mor-
tality, and low birth weight among infants, as well as at least
1 million yearly malaria deaths.1 Drug resistance has been
documented in most malaria-endemic countries, and multi-
drug resistance is spreading.1 Multidrug resistance of the ma-
laria parasite Plasmodium falciparum poses a threat to ma-
laria control in tropical developing countries worldwide.
Traditional methods for detection and surveillance of drug-
resistant malaria are cumbersome, relying on variable clinical
outcomes (in vivo resistance) or on time-consuming labora-
tory assays (in vitro resistance).2 However, new methods for
the surveillance of drug-resistant malaria using molecular
markers have recently been suggested.3 Surveillance mecha-
nisms using molecular markers may be an appropriate tech-
nology for middle-income countries such as Thailand.
Polymorphisms in the Plasmodium falciparum gene pfcrt
have been strongly correlated with in vitro chloroquine resis-
tance.4–6 Studies have reported conflicting results on an as-
sociation between polymorphisms in the falciparum gene
pfmdr1 and in vitro resistance to mefloquine.7–16 Of these two
markers, only pfcrt polymorphisms have been shown to be
associated with in vivo resistance (to chloroquine).7 Studies
are needed to demonstrate whether pfmdr1 polymorphisms
are associated with clinical resistance.
In previous work conducted in Southeast Asia,17 we found
that pfmdr1 polymorphisms (determined on parasite cultures)
were strongly related to in vitro mefloquine resistance in cul-
tured malaria isolates from across Southeast Asia. Polymor-
phisms in pfmdr1 clustered into four specific patterns: the
“wild-type” (Category I); a Tyr86 polymorphism only (Cat-
egory II); a Phe184 polymorphism only (Category III); and
Phe184 in combination with Cys1034 and/or Asp1042 (Cat-
egory IV) (Table 1). Isolates in Categories I and III were
more sensitive to chloroquine and more resistant to meflo-
quine, artesunate, and artemisinin than isolates in Categories
II and IV. Thus, these categories reflect an expected “meflo-
quine-resistant” group (Categories I and III combined) and a
“mefloquine-sensitive” group (Categories II and IV com-
bined). pfmdr1 gene amplification was also strongly associ-
ated with in vitro mefloquine resistance.
In the current study, we investigate the relationship be-
tween polymorphisms and gene amplification of pfmdr1 and
in vivo mefloquine failure in a prospective study of malaria
patients on the Thai-Myanmar border.
MATERIALS AND METHODS
This project received ethical approval from the Thai Min-
istry of Public Health, the Walter Reed Army Institute of
Research (WRAIR), and the University of North Carolina at
Chapel Hill.
The current study took place in Sangkhlaburi District, Kan-
chanaburi Province, Thailand, located near Three Pagodas
Pass at the Thai-Myanmar border. The district center is free
of malaria transmission. Malaria cases presented to local ma-
laria clinics and hospitals were almost always occupationally-
related (e.g., migrant workers from Myanmar). Malaria trans-
mission is year-round with a seasonal peak around May–
September.
Subject recruitment. We evaluated patients presenting with
fever (oral temperature  38°C) to government malaria clin-
ics and a hospital outpatient clinic in Sangklaburi. Patients
were enrolled during July 2001–August 2002. A fingerprick
blood smear, part of the standard evaluation of febrile illness,
was used to determine malaria status through Giemsa stain
and microscopic evaluation. Patients who were age 18 years
or more, with P. falciparum monoinfection and with parasit-
emia (asexual forms)  0.05% were invited to participate.
Patients who were pregnant, who had vivax infection, a his-
tory of antimalarial drug use within the past 2 weeks, bleeding
tendency (by self-reported history or based on medical
records), or severe/complicated malaria, which was defined as
any case of malaria emergency treatment of any reason or
that where referral for inpatient care was deemed necessary,
were excluded. The study was explained in detail by a re-
search nurse or investigator working at the enrollment site,
through a translator if Thai was not the primary language of
the potential subject.
Data collection. Consenting subjects were interviewed for
medical history and asked to donate 8 mL of blood by veni-
puncture. A short subject information form that captures de-
mographic data, past malaria experience, malaria treatment,
and past illnesses was also completed for each subject.
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An aliquot of blood was used to initiate malaria parasite
culture immediately at the field laboratory of the Armed
Forces Research Institute of Medical Sciences (AFRIMS) in
Sangkhlaburi prior to transfer to AFRIMS main laboratory in
Bangkok, where the in vitro assays against a panel of antima-
larial drugs (mefloquine, chloroquine, and quinine) took
place. The rest of the blood samples was stored in liquid
nitrogen and transported to AFRIMS in Bangkok for storage
at –80°C. Patients were treated with a single 750-mg dose of
mefloquine and observed for 1 hour.
Follow-up. Volunteers were asked to return for scheduled
visits on the following days (given Day 0  day of enroll-
ment): Days 3, 7, 21, 28, 35, and 42 or at any time symptoms
recurred. A history of ongoing or recurrent symptoms and
compliance with the prescribed drug regimen was obtained,
and malaria thick/thin blood smear was prepared from a fin-
gerprick. The probability of being reinfected with malaria
during the follow-up period was extremely small in the village
where this study was conducted. Patients were asked to re-
frain from entering the jungle, where the risk of infection
might be higher. The entomological inoculation rate (EIR) in
this area has been estimated to be 1–2 per year. Therefore, if
the subject was found positive for P. falciparum again within
42 days, this patient was considered “recrudescent” in our
analyses.
Eight milliliters of blood was drawn from recrudescent pa-
tients and processed as for the initial visit. Recrudescent par-
ticipants were treated with standard second-line antimalarial
regimens following the guidelines of the Thai malaria control
program for that region. Recrudescent subjects were followed
for 28 additional days with the same scheduled follow-up as
outlined above.
Laboratory methods. The in vitro drug sensitivity assay was
performed by the radioisotope microdilution technique,
slightly modified from that previously described.18
To determine genotype of parasite DNA extracted
from patient blood, we used a real-time polymerase chain
reaction (PCR; ABI Prism 7000 Sequence Detection System,
Applied Biosystems, Foster City, CA) assay as previously de-
scribed.19 This assay was used for genotype analysis of four
polymorphic sites in pfmdr1: Asn86→Tyr86,10 Tyr184→
Phe184, Ser1034→Cys1034, and Asn1042→Asp1042. Briefly,
fluorescent-labeled minor groove binding (MGB) probes
were designed specific to the polymorphic site for wild-type
or mutant species. Following amplification, the genotype of
four polymorphic sites was determined by increase in fluores-
cent emission of the wild-type or mutant probes. In one case,
DNA extraction from the blood sample did not yield DNA
that could be amplified, so DNA from parasite culture was
used. pfmdr1 gene amplification was determined using quan-
titative real-time PCR (ABI Prism 7000 Sequence Detection
System) as previously described.17 The detection of multiple
copies is accomplished by examining the standard curve com-
paring pfmdr1 to ldh in a wild-type, drug-sensitive strain of
parasite. Using this method, the ratio of ldh:pfmdr1 should
always be 1:1. The standard curve was run as a control with
each experiment to determine gene amplification. Briefly, we
designed dual-fluorescent labeled probes specific to pfmdr1
or ldh. We quantified pfmdr1 and ldh copy number based on
the emission of the probes after real-time PCR amplification.
Analysis. Data were entered into Excel spreadsheets by
study staff. Analysis was performed using SAS v8 (SAS, Inc.,
Cary, NC). Based on previous data,17 we grouped pfmdr1
genotypes into “sensitive” strains, containing pfmdr1 geno-
type Categories II and IV (Tyr86; or Phe184 with either
Cys1034, Asp1042, or both), and “resistant” strains, contain-
ing pfmdr1 genotype Categories I and III (wild type, or
Phe184), as shown in Table 1. Some isolates had mixed geno-
types. Most often, the potential combinations of genotypes
fell into the same broad category; for example, a mixed ge-
notype at position 184 falls into the Category I/III, whether it
is wild type (Category I) or polymorphism (Category III).
The planned enrollment was 200 patients, with a final sample
size of at least 150 needed to detect an association between
drug resistance and polymorphisms under the expected dis-
tributions. The relationship between molecular markers and
in vitro outcomes was assessed using 2 analysis and calculat-
ing odds ratios (OR). In vitro drug sensitivity was analyzed
directly using IC50 as a continuous variable, as well as by
dichotomizing isolates into “sensitive” and “resistant” catego-
ries based on IC50 values. For mefloquine, a resistant isolate
had an IC50 above 20 ng/mL or an IC90 above 80 ng/mL and
was categorized as sensitive if the IC50 and IC90 were below
these values.
The relationship between molecular markers and in vitro
sensitivity and the association between clinical outcomes and
in vitro susceptibility was performed using 2 analysis and t
tests. The relationship between molecular markers and clini-
cal outcome was assessed by calculating relative risks (RR)
and performing Cox proportional hazards modeling. Associa-
tions with gene amplification and recrudescent outcomes
were assessed using 2 analyses. A two-sided Fisher’s exact
test was used when expected cell-sizes were 5 or less. Non-
normally distributed IC50 values were normalized by natural
log transformation.
RESULTS
Overall, 52 patients were enrolled into the study under
mefloquine monotherapy. Demographic characteristics of the
study participants are provided in Table 2. Twenty patients
(38.5%) failed mefloquine treatment over the course of the
follow-up period and were given second-line therapy. The
mean time to recrudescence was 35.7 days (Figure 1). Four
recrudescences occurred in less than 14 days, six occurred
between 14 and 28 days, and 10 occurred between days 29 and
42 of follow-up. There were no differences between recrudes-
cent and nonrecrudescent patients in age, gender, parasit-
emia, or self-reported symptoms (Table 2). Parasitemia was
TABLE 1
Patterns of gene polymorphisms observed from isolates across South-
east Asia17 (mutated amino acid positions are shown in bold)
Category
Codon position
86 184 1034 1042
I Asn Tyr Ser Asn
II Tyr Tyr Ser Asn
III Asn Phe Ser Asn
IV Asn Phe Cys Asp
or Asn Phe Cys Asn
or Asn Phe Ser Asp
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analyzed as a predictor of recrudescence by several methods,
including rank-sum and using different cutoffs (the 75th per-
centile and 40,000 parasites/L), and no significant relation-
ship was found.
Blood samples from 2 of 52 patients did not yield quality
DNA, but adequate DNA was extracted from the culture of
one of these samples. Additionally, two blood samples
yielded genotype patterns other than the expected categories
and were excluded from categorical analyses, for a final ana-
lytic sample size of 49. Of these, 18 were Category I genotypes
(36.7%), 27 were Category III genotypes (55.1%), 3 were
Category II genotypes (6.1%), and 1 was a Category IV ge-
notype (2.0%). In total, at the initial visit there were 4 isolates
with Tyr86 (7.8%), 24 with Phe184 (47.1%), and 6 isolates
with a mixed genotype at position 184 (11.8%). There were
no Cys1034, only one with Asn1042 (2.0%), and one mixed
genotype at position 1042 (2.0%).
One of the genotypes falling outside the expected catego-
ries was a mixed tyrosine/phenylalanine phenotype at posi-
tion 184 with a mixed aspartate/asparagine phenotype at po-
sition 1042. The other sample falling outside expected com-
binations had Tyr86 and a mixed tyrosine/phenylalanine
phenotype at position 184. Of the three excluded samples
(two with unexpected genotype patterns, one with poor qual-
ity DNA), one was a patient who eventually recrudesced and
two were patients with successful malaria treatment.
pfmdr1 and in vitro drug resistance. IC50 data were avail-
able for 42 patients: 26 were patients with successful meflo-
quine therapy and 16 were patients who recrudesced. Ef-
fective sample size was 40, because two observations with
FIGURE 1. Kaplan-Meier survival curve for time to recrudescence in a population of falciparum malaria patients receiving mefloquine
monotherapy, Sangkhlaburi, Thailand, 2001–2002. Survival rates are as follows: Day 7, 44 of 46; Day 8, 38 of 42; Day 20, 36 of 41; Day 21, 34 of
40; Day 26, 25 of 35; Day 29, 21 of 33; Day 35, 11 of 28; Day 42, 5 of 24.
TABLE 2
Demographic characteristics, enrollment genotype, and selected symptoms from medical history for 52 patients receiving meflo-
quine monotherapy
Overall Recrudescent Nonrecrudescent P value*
Total, N (%) 52 20 (38.5) 32 (61.5) —
Female, N (%) 12 (23.1) 7 (21.9) 5 (25.0) 1.00
Age (mean ± SD) 28.9 ± 10.4 30.0 ± 11.8 28.2 ± 9.6 0.54†
Parasitemia‡ (median; SD) 29,040; 98,294 45,760; 119,002 22,440; 83,898 0.23†
Parasitemia range (min–max) 16–550,000 80–550,000 16–356,400
Genotype I/III, N (%) 44 (84.6) 18 (94.7) 27 (90.0)
Genotype II/IV, N (%) 6 (11.5) 1 (5.3) 3 (10.0) 1.00*
Chills, N (%) 49 (94.2) 18 (90.0) 31 (96.9) 0.55
Cough, N (%) 18 (34.6) 7 (35.0) 11 (34.4) 1.00
Diarrhea, N (%) 2 (3.9) 1 (5.0) 1 (3.1) 1.00
Malaise, N (%) 40 (76.9) 16 (80.0) 24 (46.2) 0.75
Vomiting, N (%) 23 (44.2) 9 (45.0) 14 (43.8) 1.00
* Fisher exact test, two-tailed.
† Wilcoxon rank-sum test.
‡ Parasites per microliter at initial visit to the malaria clinic.
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available IC50 were among the excluded patients (one suc-
cessfully treated and one recrudescent). None of the indi-
vidual polymorphisms observed (Tyr86, Phe184, and
Asp1042) had a significant association with higher IC50 than
the wild-type allele (Asn86, Tyr86, and Asn1042) when com-
pared by t test. IC50s were also compared across genotype
categories with the wild type (Category I) as the referent
pattern; no significant associations were observed, although
sample sizes in Categories II and IV were too small to be
meaningful.
The mean mefloquine IC50 among isolates with the pfmdr1
Category I/III (N  36) genotype was 45.9 ng/mL (95% con-
fidence interval [CI] 38.0–53.8) and 27.1 ng/mL (95% CI 14.3–
39.9) among isolates with the Category II/IV genotype (N 
4; P  0.1226). Log-transformed IC50s for chloroquine and
quinine were not different between genotype Categories I/III
versus Categories II/IV. Thus, pfmdr1 genotype patterns de-
termined directly from blood samples did not predict in vitro
drug sensitivity using a continuous scale.
IC50 was also evaluated as a dichotomous outcome, using
standard IC50 cutoffs to categorize each IC50 as “resistant” or
“sensitive.” According to the resistance IC50 cutoffs, 37
(88.1%) of the 42 isolates were resistant to mefloquine, 21
(50.0%) were resistant to chloroquine, and none were resis-
tant to quinine. No individual polymorphism or category of
genotype pattern had a significant association with dichoto-
mous in vitro outcome compared with the others. Fisher’s
exact test was performed to determine if equal proportions of
drug-resistant isolates fell into the Categories I/III versus Cat-
egories II/IV. There were no differences in level of meflo-
quine- or chloroquine-resistant isolates between blood-
derived genotype Categories I/III and II/IV.
In contrast, pfmdr1 genotype determined from the cultured
parasite did predict in vitro IC50. Previous work done by our
group found a 17% discordance between the genotype deter-
mined from blood and the genotype determined from cul-
tured parasites.19 In the current data, when culture-derived
genotypes were analyzed, there was a significant difference in
the mean mefloquine sensitivity between categories of
pfmdr1 polymorphisms. Although mean IC50s did not differ
substantially from blood data, the number of isolates in each
category was different using data from culture. Category I/III
isolates (N  33) had a mean mefloquine IC50 46.9 ng/mL
(versus 45.9 in blood DNA analysis), and Category II/IV iso-
lates (N  6) had a significant difference in the mean meflo-
quine IC50 27.7 ng/mL (versus 27.1 9 in blood DNA analysis,
P  0.0005). This suggests that culturing parasites may yield
genotype changes that might be linked to in vitro resistance.
Association between in vitro and in vivo drug resistance.
Student t tests were conducted on continuous IC50 data to
evaluate the difference in the laboratory IC50 between those
who recrudesced and those who did not recrudesce. There
were no significant differences in IC50 by recrudescence status
for any of the drugs tested (mefloquine P  0.4048, chloro-
quine P  0.2039, quinine P  0.3060).
IC50 was also considered as a dichotomous outcome, as in
the genetic analysis. Fisher’s exact test was performed to de-
termine if the proportions of in vitro drug-resistant isolates
that had recrudescent and nonrecrudescent outcomes were
equal. There were no differences in the IC50 level of meflo-
quine- or chloroquine-resistant isolates by recrudescence sta-
tus. The sensitivity of the in vitro test to detect resistance, with
the in vivo result as a gold standard, was 93.8%; however, the
specificity was only 15.4%. The kappa statistic for agreement
between these two measures was 0.07, which was not signifi-
cantly different from zero (no agreement, two-sided P 
0.6332).
pfmdr1 polymorphisms as a predictor of clinical drug resis-
tance. Polymorphisms in pfmdr1 as determined using DNA
extracted from blood were analyzed as predictors of clinical
resistance (recrudescence). Differences in clinical resistance
were analyzed by the polymorphism categories. At the initial
clinic visit, 45 members of the mefloquine-monotherapy co-
hort (91.8%) were infected with Category I/III parasites. Four
(8.2%) were infected with Category II/IV parasites. Eighteen
of 45 Category I/III patients (40.0%) and 1 of 4 Category
II/IV patients (25.0%) had recrudesced by the end of follow-
up. The relative risk of recrudescence or treatment failure
with Category I/III genotypes compared with Category II/IV
genotypes was 1.60 (95% CI 0.28, 9.07). Thus, pfmdr1 poly-
morphisms do not predict recrudescence after mefloquine
monotherapy. The relative risks for in vivo resistance with
genotype exposure are shown in Table 3.
Comparison between pfmdr1 genotypes on enrollment and
recrudescence. Genotype data were available on 14 recrudes-
cent patients at the time of recrudescence. None of the 14
patients had any polymorphism at position 86 or position
1034, both at initial visit and recrudescence. For 11 patients,
pfmdr1 genotypes were identical on enrollment and on recru-
descence. For three patients with mixed genotype on enroll-
ment, monoclonal genotypes were found on recrudescence.
Gene copy number. At the initial visit, gene amplification
determined from blood-extracted DNA was analyzed as a
predictor of recrudescence. Five patients had approximately a
2-fold elevation in pfmdr1 copy, and four of these patients
recrudesced. Of the 46 patients who did not have elevated
pfmdr1 gene copy number, 16 recrudesced, for a relative risk
of 2.30 (95% CI 1.27–4.15; Table 3). These results indicate
that infection with at least a 2-fold increase in pfmdr1 copy
number may increase the risk of recrudescence.
TABLE 3
Relative risk of recrudescence for individual SNPs, categories of
polymorphism patterns, and level of gene amplification for patients
receiving mefloquine monotherapy for malaria on the Thai-
Myanmar border (blood-derived data are shown)
N RR (95% CI)
Gene amplification
None 46 Ref –
2-fold 5 2.30 (1.27–4.15)
3-fold 0 – –
SNPs
Tyr86 3 0.62 (0.11, 3.50)
Phe184 24 0.88 (0.40, 1.92)
Ser1034 0 – –
Asp1042 1 * –
Categories
I 18 1.01 (0.31, 3.32)
II 3 0.85 (0.17, 4.39)
III 27 1.12 (0.55, 2.29)
IV 1 * –
II/IV 3 Ref –
I/III 45 1.60 (0.28, 9.07)
SNPs, single nucleotide polymorphisms; CI, confidence interval; RR, relative risk; Ref,
referent level.
* Not calculable; no patients who failed therapy were infected with parasites that exhibited
the trait of interest.
MEFLOQUINE RESISTANCE AND THE MALARIA GENE pfmdr1 589
pfmdr1 copy number was also determined for 10 patients
upon recrudescence (Figure 2). Two patients had increased
gene copy number at recrudescence. One patient had para-
sites with 2-fold increase in copy number at both admission
and recrudescence. Parasites from the other patient did not
have increased pfmdr1 copy number on admission but had
2-fold increased copy number on recrudescence.
DISCUSSION
As rates of drug-resistant malaria rise, research into the
mechanisms contributing to the development of drug resis-
tance and ways to prevent this from occurring becomes more
and more vital. Thailand is a country with a successful malaria
control program but which suffers from multidrug-resistant
malaria strains at its borders due to fluctuating populations
with little malaria immunity. Because of the use of meflo-
quine monotherapy as first-line therapy in parts of the coun-
try, at the time of the study Thailand was in an ideal region to
research the role of the P. falciparum gene pfmdr1in meflo-
quine drug resistance.
In this study, we investigated whether pfmdr1 polymor-
phisms were predictive of drug resistance in vivo. In a cohort
of patients treated with mefloquine monotherapy, we found
that pfmdr1 genotype determined on patient blood was not
statistically associated with mefloquine, chloroquine, or qui-
nine IC50s. However, when genotype was determined on
DNA from cultured parasites, a significant association be-
tween pfmdr1 genotype categories and mefloquine IC50 was
observed. These results indicate that selection of pfmdr1
genotypes may occur when parasites become adapted to cul-
ture. This might explain another observation made in this
paper, namely that there was a poor correlation between in
vitro and in vivo drug resistance. Polymorphisms among para-
sites that have been adapted to culture might be expected to
correlate more closely with resistance determined from in
vitro test than resistance determined from clinical outcome.
Clinically, we found a slightly increased risk of recrudes-
cence with the resistant pfmdr1 genotype Categories I and III
(RR 1.60), which was statistically non-significant. However,
increased pfmdr1 copy number was predictive of recrudes-
cence. Those with a 2-fold increase in copy number at the
initial visit were more likely to recrudesce, with a relative risk
of recrudescence of 2.30 compared with those with no pfmdr1
amplification (95% CI 1.27–4.15). This result affirms labora-
tory studies of parasite isolates, which have found increased
expression of pfmdr1 mRNA in mefloquine-resistant strains
compared with mefloquine-sensitive strains.20–22 In a rodent
model of malaria, the putative pfmdr1 homologue was 2- to
3-fold amplified in rodents infected with mefloquine-resistant
malaria strains.23 Studies in Thailand and other Southeast
Asian countries have shown an association between increased
gene copy number and in vitro resistance to mefloquine,10,24
with conflicting evidence about the independent role of poly-
morphismss at codon 86. Other studies in Thailand and else-
where, however, did not observe a relationship between drug
resistance and gene amplification.14,25 This could indicate dif-
fering mechanisms of resistance in different geographical ar-
eas or that results of studies examining gene copy number
may be different depending on the background antimalarial
use in the region. Evaluation of the expression of pfmdr1
during human infection may be an important next step in
resolving its role in mefloquine drug resistance.
The methods developed by our group19 were designed to
detect amplification at specific levels of confidence. The 90%
confidence level corresponded to a pfmdr1:ldh copy number
ratio of 1.7 to 1; thus, at 90% confidence we could detect
approximately a 2-fold level of amplification. At the 95%
confidence level, the pfmdr1:ldh ratio was 3.05 to 1, thus we
could detect 3-fold amplification with 95% confidence. How-
ever, no isolates exhibited 3-fold amplification at the initial
clinic visit, so the more sensitive 2-fold detection was used.
These methods can be performed on parasite DNA extracted
directly from blood samples, and the technology is not only
effective but is not unaffordable for low-income countries.
In our data, gene copy numbers determined for cultured
parasites did not have good agreement with gene copy num-
bers determined directly from patient blood, agreeing on only
25% of samples (data not shown). Most studies of molecular
markers for drug resistance have focused on traditional in
vitro resistance measures involving culture or have used DNA
from cultured parasites. The correlation between in vitro and
in vivo outcomes has not been established in these settings.
The genotype determined from a cultured isolate may not be
the same genotype as the predominant infecting strain, as
adaptation to culture may select for one strain of a multi-
clonal infection or may induce changes in the parasite geno-
type. In our study, we found that the in vitro test had 93%
sensitivity and 15% specificity for detecting mefloquine treat-
ment failure. By contrast, a comparison of in vitro and in vivo
chloroquine resistance in Cameroon found the in vitro test
to have 67% sensitivity and 84% specificity, with a kappa
FIGURE 2. Frequency of pfmdr1 gene amplification among pa-
tients receiving mefloquine monotherapy for malaria at the Thai-
Myanmar border.
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statistic for agreement between the two measures that was
much higher than the one presented here (0.48 versus 0.07).26
Additionally, the positive predictive value for in vitro resis-
tance in our study was only 40.5%. Other strong method-
ologic literature in this area is lacking. The disparity between
in vivo and in vitro resistance could be due to evolutionary
selection in culture or other confounding factors such as dif-
ferences in drug metabolism, or preexisting antimalarial im-
munity could also contribute. However, there remains a lack
of research about the proper interpretation of in vitro resis-
tance measures as applied to in vivo outcomes.
Previous work done by our group found that the main fac-
tor in predicting recrudescence in hospitalized patients under
artesunate therapy was the initial parasite burden of the pa-
tient.27 However, the current study found no relationship be-
tween parasite burden and recrudescence. The conflicting re-
sults of our two studies could be due to several reasons. The
use of hospitalized patients in the previous study reflects a
more severe malaria infection, and patients might be ex-
pected to have more extreme parasite burdens. The current
study has a small sample size, but the pharmacokinetics of the
malaria therapy used are also different. Mefloquine, used in
the current project, has a long half-life and is effective against
blood parasite levels for a longer period of time. Artesunate,
however, is quickly metabolized; patients with higher parasite
burden may recrudesce more because the blood drug level
does not remain high enough to affect the entire parasite
population.
Our data are consistent with other studies of pfmdr1 mo-
lecular markers as predictors of mefloquine treatment failure.
Two studies28,29 found that pfmdr1 point mutations did not
predict recrudescence. One of these studies29 also found that
pfmdr1 gene amplification was associated with mefloquine
failure. Another study was unable to analyze polymorphisms
as predictors of recrudescence because mefloquine treatment
was efficacious in the study area.16
Due to the prospective study design, this study has many
strengths. We were able to evaluate pfmdr1 genotype both
before treatment and at the time of recrudescence. Patients
were closely followed for recrudescence with regular blood
smears. The setting of this study also gave reassurance against
the possibility for reinfection, as the immediate Sangkhlaburi
District carries a very low risk for malaria, and patients must
venture further into the jungle to increase their risk. This
study also has several analytical advantages, including real-
time PCR technology developed to rapidly detect polymor-
phisms, the ability to test both blood and culture parasites
from patients for polymorphisms, and the availability of IC50
data. This study is the second study to our knowledge to
evaluate pfmdr1 polymorphisms and drug resistance in hu-
man populations, and is the first in Southeast Asia, which has
proved to be a hot spot for the development of resistance.
However, there were also several drawbacks in conducting
this study, the greatest of which is the small sample size. Me-
floquine treatment failure records at malaria clinics and pre-
liminary data from this study encouraged the Thai Ministry of
Public Health to change the first-line malaria treatment regi-
men from mefloquine alone to a mefloquine-artesunate com-
bination, thus cutting the study short and limiting power. Ad-
ditionally, other factors contributing to drug resistance and/or
recrudescence were not measured, such as immune status,
individual nutritional factors, and drug metabolism. Despite
the evidence in the literature that pfmdr1 is correlated with
mefloquine drug resistance, there could be another gene
linked to pfmdr1 that is actually responsible for resistance.
Although the risk of reinfection in this population is low,
strain typing was not performed; therefore, reinfection cannot
be ruled out. However, any misclassification that might have
labeled a truly reinfected individual as a recrudescent indi-
vidual would have been nondifferential across genotype ex-
posure groups, resulting in a bias toward the null.
Our results suggest that pfmdr1 gene polymorphisms are
probably not a useful surveillance tool for detecting drug-
resistant malaria in Thailand; however, the relationship be-
tween gene amplification and recrudescence may be useful in
evaluating potential for malaria recrudescence.
The use of real-time PCR allowing for direct detecting of
potential polymorphisms could be an appropriate technology
for study of molecular markers of antimalarial resistance, and
polymorphisms in pfmdr1 deserve further investigation. It
may be difficult to repeat this study because there are few
endemic areas in the world where mefloquine monotherapy is
used today. However, application of the technology to evalu-
ate resistance development to artemisinin-based combination
therapy (ACT), which has mefloquine or its related com-
pound, lumefantrine, as a partner drug, would be of interest,
as pfmdr1 has been shown in vitro to be associated with re-
duced artemisinin sensitivity as well.17 Because ACTs are be-
ing introduced in many endemic areas, especially in sub-
Saharan Africa, real-time PCR–based surveillance for pfmdr1
polymorphisms could become an important public health
tool.
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